Spironolactone to Improve Pregnancy-Associated Hypertension Trajectories (NCT07041281)
🩺 Plain-English Summary (8th-Grade Level)
The hypertensive disorders of pregnancy (preeclampsia and gestational hypertension) are associated with increased long-term maternal risk of developing cardiovascular disease. Recent evidence suggests that activation of the mineralocorticoid receptor promotes ongoing susceptibility to hypertension in women following hypertensive disorders of pregnancy. In addition, women with overweight/obesity are at increased risk for progression to chronic hypertension after experiencing hypertensive disorders of pregnancy. Among women with hypertensive disorders of pregnancy and pre-pregnancy overweight/obesity, the investigators will conduct a randomized trial to test the effect of pharmacologically blocking the mineralocorticoid receptor for three months after delivery on blood pressure and cardiac remodeling at nine months postpartum.
Who can join: To join this study, participants generally need to meet the listed inclusion criteria (5 items) and avoid the listed exclusions (16 items).
Location: Massachusetts General Hospital — Boston, Massachusetts
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistCheck every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).
Usually NOT eligible if any of the following apply:
- Exclusion Criteria:
- LV ejection fraction \<50% or history of clinical heart failure with reduced or preserved ejection fraction
- Hypertrophic or other genetic cardiomyopathy
- Hyperkalemia: potassium \>5.3 mEq/L
- BMI at screening ≥50 kg/m2
- Pre-pregnancy diabetes
- Estimated glomerular filtration rate (eGFR) \<60mL/min/1.73 m2
- Cirrhosis
- Primary aldosteronism
- Intention to become pregnant within 9 months
- Active substance abuse
- Other serious medical illnesses or concerns about protocol adherence/ mortality within 9 months
🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.
📍 All Participating Trial Locations (3 Sites)
- Massachusetts General Hospital — Boston, Massachusetts
- Brigham and Women's Hospital — Boston, Massachusetts
- University of Pittsburgh Magee-Womens Hospital — Pittsburgh, Pennsylvania
📞 Contact the Study Coordinator
Phone: (617) 726-1843
Email: mhonigberg@mgh.harvard.edu
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Preeclampsia
- The ACHIEVE Trial: Achieving Longer Gestation in Preeclampsia Via Antihypertensive Therapy. — Birmingham, Alabama
- Predictors of Aspirin Failure in Preeclampsia Prevention — New York, New York
- Biobank on Prematurity, Preeclampsia and Other Pregnancy Complications — Québec,
- Relationship Between Aspirin Metabolism and Markers of Metabolic Dysfunction Among Pregnant Persons at Risk of Pre-eclampsia — Knoxville, Tennessee
- Clinician Notification to Increase Aspirin Prophylaxis for Preeclampsia Prevention — Boston, Massachusetts
- Optimizing Preeclampsia Postpartum With Point-of-care Ultrasound — Orange, California
Explore by condition: All Preeclampsia clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.